Major Depressive Disorder Japan Drug Forecast and Market Assessment to 2025 [Updated: 05102016] Prices from USD $4995

03:06 EST 28 Feb 2017 | BioPortfolio Reports

Major Depressive Disorder Japan Drug Forecast and Market Assessment to 2025


Major depressive disorder MDD is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes MDEs, where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically topselling products such as Eli Lilly's Cymbalta and Otsuka/BMS' Abilify have occurred, and recent launches of Lundbeck/Takeda's Trintellix and Otsuka/Lundbeck's Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising latestage pipeline products into the market during the forecast period, all of which are directed towards treatmentresistant patients, a significant unmet need.

GlobalData estimated that MDD drug sales in Japan during 2015 reached $315.0m, making it the second largest single market in the 7MM. GlobalData estimates that the Japanese MDD market will be turbulent during the forecast period with important patent losses occurring, such as Otsuka/BMS' Abilify, Eli Lilly's Cymbalta, and Lundbeck/Allergan's Lexapro. Effexor will see the highest growth rate of any drug in the Japanese MDD market over the 10year forecast.

*This is an ondemand report and will be delivered within 24 hrs. excluding weekends of the purchase.


Overview of MDD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Japan from 20152025.
Analysis of the impact of key events as well the drivers and restraints affecting Japan MDD market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for MDD.
Effectively plan your MA and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and indepth analysis of drug performance
Obtain sales forecast for drugs from 20152025 in Japan.

Original Article: Major Depressive Disorder Japan Drug Forecast and Market Assessment to 2025 [Updated: 05102016] Prices from USD $4995


More From BioPortfolio on "Major Depressive Disorder Japan Drug Forecast and Market Assessment to 2025 [Updated: 05102016] Prices from USD $4995"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Anxiety Disorders
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...